Lazard Asset Management
BNGO icon

Lazard Asset Management’s Bionano Genomics BNGO Stock Holding History

Lazard Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed -$43K – 2306
2022
Q4 		$43K Hold
50
– – ﹤0.01% 1886
2022
Q3 		$54K Hold
50
– – ﹤0.01% 1763
2022
Q2 		$41K Hold
50
– – ﹤0.01% 1899
2022
Q1 		$77K Buy
+50
New +$67.5K ﹤0.01% 1519

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Lazard Asset Management's BNGO Position: Q1 2023 in Review

Lazard Asset Management sold out of Bionano Genomics (BNGO) in Q1 2023, closing a stake of 50 shares — an estimated $43K sold.

Lazard Asset Management first reported a position in BNGO in Q1 2022 and held it in 4 quarters. The position peaked at $77K in Q1 2022. 126 funds tracked by Wall St. Rank hold BNGO as of Q1 2023.

  • Lazard Asset Management reported no remaining Bionano Genomics position as of Q1 2023 after selling out during the quarter.
  • Lazard Asset Management sold 50 Bionano Genomics shares in Q1 2023, an estimated $43K.
  • Lazard Asset Management first reported a position in Bionano Genomics in Q1 2022 and held it in 4 quarters.
  • Lazard Asset Management's Bionano Genomics position peaked at $77K in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2023.

Based on Lazard Asset Management's 13F filing for Q1 2023, filed 15 May 2023.